GlassScriptPhysician profile
Julio A Savinon
NPI 1851357354
$3,547.40
in general payments reported to CMS, 2019-2025
30 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $419 · 2021: $639 · 2022: $356 · 2023: $569 · 2024: $253 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $490.94 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $467.06 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $346.83 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $326.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $241.14 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
| Merck Sharp & Dohme LLC | $231.83 | 2019-2022 | |
| Insulet Corporation | $203.09 | 2019-2023 | Omnipod |
| Amgen INC. | $175.53 | 2019-2025 | Evenity, Prolia, Prolia |
| Medtronic, INC. | $101.40 | 2022 | |
| Allergan, INC. | $96.72 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.86 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $89.63 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $87.69 | 2019-2022 | |
| Exact Sciences Corporation | $82.68 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $74.47 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $62.47 | 2019-2020 | |
| Glaxosmithkline, LLC. | $60.25 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $45.40 | 2019 | |
| Eisai INC. | $30.77 | 2021 | |
| Abbvie INC. | $30.13 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $28.28 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $27.16 | 2023 | Aptima, Thinprep 2000 Processor |
| Arbor Pharmaceuticals, INC. | $25.12 | 2021 | |
| Esperion Therapeutics, INC. | $21.77 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.07 | 2022 | |
| Dexcom, INC. | $19.02 | 2021 | |
| Mannkind Corporation | $18.54 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.72 | 2023 | Quviviq |
| Pfizer INC. | $16.44 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Savinon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.